Paragon Bioservices Celebrates Grand Opening of its World-Class Gene Therapy Biomanufacturing Facility

PARAGON BIOSERVICES, INC. | April 11, 2019 | 145 views

BALTIMORE, April 11, 2019 /PRNewswire/ --Paragon BioServices, the leading private equity-backed biologics contract development and manufacturing organization (CDMO) with proven expertise in gene therapy and next-generation vaccines, celebrated this morning the grand opening of its new, world-class and state-of-the-art 200,000 square-foot GMP gene therapy biomanufacturing facility in Maryland's Anne Arundel County. The event brought together state and regional political and biopharmaceutical industry leaders. Distinguished guests and speakers at the event "With this new and impressive commercial-scale facility, Paragon Bioservices is helping to solidify Maryland's position as a premiere location for leading-edge biomanufacturing.

Spotlight

BioCare Copenhagen

BioCare Copenhagen is a Danish bio-venture company specialising in food supplements containing microbial compounds, targeting gastrointestinal disorders, infections and immunity.

OTHER ARTICLES
MedTech

Top 10 biotech IPOs in 2019

Article | July 13, 2022

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More
MedTech

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | July 12, 2022

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More
MedTech

Closing bacterial genomes from the human gut microbiome using long-read sequencing

Article | October 7, 2022

In our lab, we focus on the impact of the gut microbiome on human health and disease. To evaluate this relationship, it’s important to understand the particular functions that different bacteria have. As bacteria are able to exchange, duplicate, and rearrange their genes in ways that directly affect their phenotypes, complete bacterial genomes assembled directly from human samples are essential to understand the strain variation and potential functions of the bacteria we host. Advances in the microbiome space have allowed for the de novo assembly of microbial genomes directly from metagenomes via short-read sequencing, assembly of reads into contigs, and binning of contigs into putative genome drafts. This is advantageous because it allows us to discover microbes without culturing them, directly from human samples and without reference databases. In the past year, there have been a number of tour de force efforts to broadly characterize the human gut microbiota through the creation of such metagenome-assembled genomes (MAGs)[1–4]. These works have produced hundreds of thousands of microbial genomes that vastly increase our understanding of the human gut. However, challenges in the assembly of short reads has limited our ability to correctly assemble repeated genomic elements and place them into genomic context. Thus, existing MAGs are often fragmented and do not include mobile genetic elements, 16S rRNA sequences, and other elements that are repeated or have high identity within and across bacterial genomes.

Read More

Selexis Cell Line Development Strategies

Article | February 11, 2020

In today’s biotechnology landscape, to be competitive, meet regulations, and achieve market demands, “we must apply Bioprocessing 4.0,” said Igor Fisch, PhD, CEO, Selexis. In fact, in the last decade, “Selexis has evolved from cloning by limiting dilution to automated cell selection to nanofluidic chips and from monoclonality assessment by statistical calculation to proprietary bioinformatic analysis,” he added. Single-use processing systems are an expanding part of the biomanufacturing world; as such, they are a major component of Bioprocessing 4.0. “At Selexis, we use single use throughout our cell line development workflow. Currently, we have incorporated single-use automated bioprocessing systems such as ambr® and the Beacon® optofluidic platform for accelerated cell line development. By using these systems and optimizing our parameters, we were able to achieve high titers in shake flasks. Additionally, the Beacon systems integrate miniaturized cell culture with high-throughput liquid handling automation and cell imaging. This allows us to control, adjust, and monitor programs at the same time,” noted Fisch.

Read More

Spotlight

BioCare Copenhagen

BioCare Copenhagen is a Danish bio-venture company specialising in food supplements containing microbial compounds, targeting gastrointestinal disorders, infections and immunity.

Related News

Cell & Gene Therapy World: Accelerate your cell therapy research

Fisher BioServices | January 22, 2016

The advancements in cell therapy are increasing at a rapid pace and are transforming the way we think about medicine. Whether in research or in the clinic, scientific innovators are acutely aware that every moment counts when working with these valuable therapies. To facilitate knowledge sharing and collaboration, Thermo Fisher Scientific is proud to support the 12th Annual Cell & Gene Therapy World event.

Read More

The Evolution of Public Health Research: Snow’s Dilemma

Fisher BioServices | February 09, 2016

Since the dawn of humanity, we have observed nature and hypothesized reasons behind how and why things happen. With the development of civilization, we standardized the methods with which we test, observe, and analyze nature, and this gave birth to the field of science. As far as the defined field of study now known as Epidemiology and Public Health, it can be argued that it began in 1854, with a cholera outbreak in the Soho district of London and a physician named John Snow (who knew more than nothing).

Read More

Thermo Fisher Scientific Expands Global Footprint to Support Cell and Gene Therapy Clinical Trials in Japan

Fisher BioServices | October 03, 2016

To help meet increasing demand for cell and gene therapy clinical trial support around the globe, Thermo Fisher Scientific, the world leader in serving science, today announced the expansion of its Fisher BioServices cryogenic service capabilities in Japan. This expansion enables its customers to seamlessly conduct clinical trials across multiple geographies and provides patients around the world with access to life changing therapies.

Read More

Cell & Gene Therapy World: Accelerate your cell therapy research

Fisher BioServices | January 22, 2016

The advancements in cell therapy are increasing at a rapid pace and are transforming the way we think about medicine. Whether in research or in the clinic, scientific innovators are acutely aware that every moment counts when working with these valuable therapies. To facilitate knowledge sharing and collaboration, Thermo Fisher Scientific is proud to support the 12th Annual Cell & Gene Therapy World event.

Read More

The Evolution of Public Health Research: Snow’s Dilemma

Fisher BioServices | February 09, 2016

Since the dawn of humanity, we have observed nature and hypothesized reasons behind how and why things happen. With the development of civilization, we standardized the methods with which we test, observe, and analyze nature, and this gave birth to the field of science. As far as the defined field of study now known as Epidemiology and Public Health, it can be argued that it began in 1854, with a cholera outbreak in the Soho district of London and a physician named John Snow (who knew more than nothing).

Read More

Thermo Fisher Scientific Expands Global Footprint to Support Cell and Gene Therapy Clinical Trials in Japan

Fisher BioServices | October 03, 2016

To help meet increasing demand for cell and gene therapy clinical trial support around the globe, Thermo Fisher Scientific, the world leader in serving science, today announced the expansion of its Fisher BioServices cryogenic service capabilities in Japan. This expansion enables its customers to seamlessly conduct clinical trials across multiple geographies and provides patients around the world with access to life changing therapies.

Read More

Events